Honda, Nissan, Novo Nordisk, Eli Lilly

The company is well-positioned to continue gaining momentum against Novo in weight loss while simultaneously leading the ...
Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...
Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with ...
CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks.
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...